Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double Blind, Placebo Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients With C3 Glomerulopathy

NCT03301467 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT03301467
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03301467 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double Blind, Placebo Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients With C3 Glomerulopathy
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Completed
Start date
September 29, 2017
Completion date
October 27, 2021
Enrollment
57 (actual)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

c3 glomerulopathy (c3g)